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Abstract
Background
Ambulatory function predicts morbidity and mortality and may be influenced by cardiopulmo-
nary dysfunction. Persons living with HIV (PLWH) suffer from a high prevalence of cardiac
and pulmonary comorbidities that may contribute to higher risk of ambulatory dysfunction as
measured by 6-minute walk test distance (6-MWD). We investigated the effect of HIV on 6-
MWD.
Methods
PLWH and HIV-uninfected individuals were enrolled from 2 clinical centers and completed a
6-MWD, spirometry, diffusing capacity for carbon monoxide (DLCO) and St. George’s Respi-
ratory Questionnaire (SGRQ). Results of 6-MWD were compared between PLWH and unin-
fected individuals after adjusting for confounders. Multivariable linear regression analysis
was used to determine predictors of 6-MWD.
Results
Mean 6-MWD in PLWH was 431 meters versus 462 in 130 HIV-uninfected individuals (p =
0.0001). Older age, lower forced expiratory volume (FEV1)% or lower forced vital capacity
(FVC)%, and smoking were significant predictors of decreased 6-MWD in PLWH, but not
HIV-uninfected individuals. Lower DLCO% and higher SGRQ were associated with lower 6-
MWD in both groups. In a combined model, HIV status remained an independent predictor
of decreased 6-MWD (Mean difference = -19.9 meters, p = 0.005).
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Conclusions
HIV infection was associated with decreased ambulatory function. Airflow limitation and
impaired diffusion capacity can partially explain this effect. Subjective assessments of respi-
ratory symptoms may identify individuals at risk for impaired physical function who may ben-
efit from early intervention.
Introduction
Half of persons living with HIV (PLWH) living in the United States are over 50 years old [1]
and are increasingly affected by age-associated and chronic comorbid conditions [2, 3]. HIV
infection is similarly associated with increased frailty, as well as declines in lung and cardiovas-
cular health [4] that have potential impact on physical function. In one large study of United
States male veterans, decline in scale-based self-reported physical function per year was greater
in PLWH than HIV-uninfected individuals, and chronic pulmonary disease appeared to
uniquely modify this effect [5]. While there have been a host of studies assessing chronic pul-
monary disease and aberrant pulmonary physiology in PLWH [6–8], there has been limited
research specifically assessing cardiopulmonary functional capacity, highlighting the lack of
insight into the clinical determinants of declining physical function in this high-risk group [9].
Additionally, in heterogenous populations of PLWH, the relationships among demographic
and clinical variables and measures of physical function are relatively unexplored [10].
Six-minute walk distance (6-MWD) is a validated metric for assessing functional aerobic
exercise capacity. It is a predictor of mortality in the general population [9, 11] and in PLWH
[9]. Studies in a predominantly male veteran population found that HIV was not an indepen-
dent predictor of 6-MWD, but that forced expiratory volume in one second (FEV1) percent-
predicted and radiographic emphysema were uniquely associated with decreased 6-MWD in
PLWH [12, 13]. These findings suggest a link between the increased risk of obstructive pulmo-
nary disease [6, 7] and diminished respiratory-related health status [14] that are observed in
PLWH in epidemiologic studies, but conclusions are not generalizable due to the relatively
homogenous cohort.
We assessed the independent effect of HIV on subjective and objective measures of cardio-
pulmonary function in a cohort of PLWH and HIV-uninfected individuals and identified asso-
ciated clinical and demographic variables as well as potential biomarkers.
Materials and methods
Participants
Individuals with documented HIV infection as well as HIV-uninfected individuals who were
18 years of age or older were recruited from the University of Pittsburgh and University of Cal-
ifornia San Francisco as part of the Pittsburgh HIV Lung Research Cohort [8, 15]. Participants
were recruited using posted advertisements and from the Multicenter AIDS Cohort Study
(MACS) [16], the Women’s Interagency HIV Study (WIHS) [17], and the Pitt Center for
Treatment research registry. Exclusion criteria were acute respiratory symptoms (new or
increasing cough or shortness of breath) within the previous four weeks, prior thoracic sur-
gery, or contraindication to either pulmonary function testing or 6-MWD testing. The Univer-
sity of Pittsburgh and University of California San Francisco IRBs approved the protocol, and
all participants signed written informed consent.
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Data collection/methods
Standardized questionnaires were used to obtain demographic and baseline clinical data
including smoking history and adherence to antiretroviral therapy (ART). Review of the elec-
tronic medical record or MACS and WIHS databases were used to obtain CD4+ T-lymphocyte
count (CD4) and plasma HIV RNA levels within 6 months from current visit. Participants per-
formed pre- and post-bronchodilator spirometry and measurement of the diffusing capacity
for carbon monoxide (DLCO) per American Thoracic Society (ATS) and European Respiratory
Society (ERS) standards [18–20]. Spirometry reference values were determined using the third
National Health and Nutrition Examination Survey equations [21]. Equations by Neas et al.
were used as reference values for DLCO and DLCO percent predicted was adjusted for hemoglo-
bin and carboxyhemoglobin [22]. Only tests meeting ATS standards or deemed acceptable by
a trained pulmonologist as acceptable were included in analysis [18, 21–24]. Respiratory symp-
toms were assessed by patient self-report of new or increasing cough or dyspnea. Assessments
of respiratory symptoms were performed using a modified version of the St George’s Respira-
tory Questionnaire (SGRQ) and the Modified Medical Research Council (MMRC) question-
naire. SGRQ is a 50-item questionnaire that measures the domains of symptoms, activity and
impact with s ranging from 0–100 with higher scores indicating worse functional impairment
[25]. MMRC is a five-point scale based on degree of breathlessness generated by various physi-
cal activities [26]. All participants completed a six-minute walk distance (6-MWD) test accord-
ing to the American Thoracic Society guidelines [18, 27]. Total distance walked was recorded
per standard protocol. The reference range of the 6-MWD test is age- and gender-dependent
with mean (SD) of 571 (90) meters in healthy adults [28].
Statistical analysis
Demographic, clinical and laboratory markers as well as PFT measurements were compared
between PLWH and HIV-uninfected groups using Student’s t test or Chi-squared test. Corre-
lation coefficients between specific variables and 6-MWD (Pearson correlations) were calcu-
lated separately by HIV status. Additionally, we used a backward stepwise approach using
predictors with P� 0.2 from bivariate analyses (besides height as a known 6-MWD predictor)
for multivariable linear regression models to determine predictors of 6-MWD in PLWH and
HIV-uninfected participants. An interaction between each variable and HIV status was calcu-
lated to test predictors of 6-MWD in PLWH versus HIV-uninfected individuals. Each model
was tested for linearity of relationship, distribution of residual, high influential observations,
and interactions. A P value less than 0.05 was considered statistically significant. All analyses
were performed in STATA 14.2 (StataCorp., College Station, TX).
Results
Characteristics of the study population
Two hundred ninety-seven PLWH and 130 HIV-uninfected participants were included
(Table 1). Median age was 51 years, 40% were female, 51% were African-American. Median
pack-year smoking in HIV-infected individuals was 7.8 vs. 5.5 in HIV-uninfected individuals
(p = 0.06). Most HIV-infected participants were receiving ART and 65% had undetectable
plasma HIV RNA levels. Median CD4 cell counts were generally within normal range (median
CD4 cells/μL, 618; IQR 434–856).
Post-bronchodilator percent-predicted forced expiratory volume in one second (FEV1)%
predicted, forced vital capacity (FVC)% predicted and FEV1/FVC were similar between
PLWH and HIV-uninfected individuals, but DLCO% predicted was significantly lower in
Impaired physical function in HIV
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Table 1. Distribution of demographic and clinical variables by HIV status.
All
(n = 427)
HIV-uninfected
(n = 130)
PLWH
(n = 297)
P value
Age, median years (IQR) 51 (44–57) 51 (43–57) 52 (45–56) 0.94
Female, % (n) 39.6 (165) 46.2 (60) 35.4 (105) 0.035
Race, % (n)
Caucasian 41.5 (177) 46.2 (60) 39.4 (117) 0.32
African-American 51.3 (219) 48.5 (63) 52.5 (156)
Other 7.2 (31) 5.3 (7) 8.1 (24)
Site, % (n)
Pittsburgh 73.3 (313) 74.6 (97) 72.7 (216) 0.69
University of California San Francisco 26.7 (114) 25.4 (33) 27.3 (81)
Height cm, median (IQR) 173 (165–180) 170 (163–178) 173 (165–180) 0.07
Weight kg, median (IQR) 78 (70–91) 82 (73–95) 78 (69–90) 0.06
Smoking status, % (n)
Never 30.9 (132) 36.2 (47) 28.6 (85) 0.27
Current 44.3 (189) 42.3 (55) 45.1 (134)
Former 24.8 (106) 21.5 (28) 26.3 (78)
Pack-year, median (IQR)� 15.3 (6.3–31.2) 13.9 (5.7–26.3) 16.1 (6.9–32.3) 0.26
Illicit drug usage, % (n) 88.3 (377) 86.2 (112) 89.2 (265) 0.36
Hemoglobin g/dL, median (IQR) 13.8 (12.7–14.8) 14.2 (12.9–15.0) 13.7 (12.7–14.7) 0.11
VL, median copies/ml (IQR)1 - - 39 (19–63) - -
VL undetectable, % (n)1 - - 64.5 (182) - -
CD4 cell count/μL, median (IQR)2 - - 618 (434–856) - -
Current ART, % (n)3 - - 92.6 (275) - -
SBP mmHg, median (IQR) 125 (115–138) 127 (118–139) 124 (114–137) 0.07
DBP mmHg, median (IQR) 79 (72–87) 81 (73–89) 79 (72–86) 0.38
FEV1% post-BD, median (IQR)
4 92 (79–104) 93 (80–103) 92 (77–105) 0.53
FVC % post-BD, median (IQR)4 91 (80–102) 92 (83–103) 91 (79–101) 0.33
FEV1/FVC post-BD, median (IQR)
4 80 (75–84) 80 (75–84) 80 (75–84) 0.93
DLCO %, median (IQR)
5 81 (70–92) 86 (77–95) 79 (67–89) 0.0001
MMRC score, median (IQR)6 0 (0–1) 0 (0–1) 1 (0–1) 0.038
SGRQ score, median (IQR)
Total 7.1 (2.1–22.5) 4.1 (0.8–16.7) 8.6 (2.9–24.7) 0.0004
Symptom 11.1 (4.9–27.1) 10.2 (0.0–21.4) 12.9 (4.9–28.9) 0.047
Activity 12.2 (0.0–35.8) 6.2 (0.0–29.6) 12.5 (0.0–41.3) 0.007
Impact 1.9 (0.0–11.4) 0.0 (0.0–6.7) 3.6 (0.0–13.2) 0.003
6-MWD, mean; median m (IQR) 441;446 (388–493) 462;469 (418–512) 431;435 (376–481) 0.0001
PLWH: People living with HIV; IQR: interquartile range; Pack-year: median number packs of cigarettes smoked per day multiplied by number of years smoking; VL:
HIV viral load; CD4: CD4 T-lymphocyte count; ART: antiretroviral therapy; SBP: systolic blood pressure; DBP: diastolic blood pressure; FEV1: forced expiratory
volume during 1st second; FVC: forced vital capacity; DLCO: diffusing capacity of the lungs for carbon monoxide adjusted for hemoglobin and carboxyhemoglobin; BD:
bronchodilator test; % = percent-predicted; MMRC: Modified Medical Research Council dyspnea score; SGRQ: St George’s Respiratory Questionnaire; 6-MWD: Six
minute walk distance
1n = 282
2n-284
3n = 297
4n = 422
5n = 425
6n = 316
� n = 295
P <0.003 are significant after adjusting for multiple comparison.
https://doi.org/10.1371/journal.pone.0212975.t001
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PLWH (median 79 vs. 86, p = 0.0001). Average 6-MWD was significantly shorter for PLWH
than for HIV-uninfected participants (mean 431 meters vs. 462 meters, p = 0.0001) and fre-
quency of 6-MWD <350 meters in HIV-uninfected and PLWH was 5.4% vs. 16.2%, respec-
tively (P = 0.002).
PLWH were also more likely to report respiratory symptoms as evidenced by the signifi-
cantly worse SGRQ (median 8.6 vs 4.1, p = 0.0004) and MMRC scores (median 1.0 vs 0.0,
p = 0.038). All three dimensions of SGRQ including symptom, activity and impact were signif-
icantly worse in PLWH (Table 1).
Predictors of 6-MWD
Bivariate analysis: Lower FEV1%, FVC%, and DLCO% were associated with a shorter 6-MWD
in both groups. Higher weight, MMRC and SGRQ score (where higher scores indicate greater
symptom burden) were associated with shorter 6-MWD in both groups. In both groups, all
three dimensions of SGRQ were significantly associated with lower 6-MWD. Spearman rho (P
value) for symptoms, activity and impact score in PLWH was -0.13 (0.030), -0.25 (<0.0001),
-0.26 (<0.0001). In the HIV-uninfected group, these correlations (P value) were -0.30
(0.0005), -0.40 (<0.0001), -0.34 (0.0001). Among PLWH, older age, Pittsburgh site and pack-
year smoking were associated with shorter 6-MWD, whereas African-American race was asso-
ciated with shorter 6-MWD in HIV-uninfected participants. Direction and/or magnitude of
relationship between 6-MWD and age, pack-year smoking and site of recruitment were signifi-
cantly different between the PLWH and -uninfected groups as reflected by the P value of inter-
action (Table 2).
Multivariable analysis
In PLWH, DLCO% (β = 0.8), FEV1% (β = 0.5), age (β = -1.0 per year), height (β = 1.6 per cm),
weight (β = -1.1 per Kg), pack-year smoking (β = -0.7), and SGRQ (β = -0.9) were indepen-
dently associated with 6-MWD. White race was also associated with an average 25.6 meters
greater 6-MWD. Both FVC% and FEV1% were independently associated with higher 6-MWD
(β = 0.6). Each was entered the model separately given collinearity between the two values.
CD4 count and HIV viral load were not associated with 6-MWD in PLWH. In contrast,
DLCO% (β = 1.3), SGRQ (β = -1.7) and weight (β = -0.7) were the only independent predictors
of 6-MWD in HIV-uninfected participants (Table 3). These models predicted 41% and 23% of
6-MWD variation in PLWH and HIV-uninfected participants, respectively.
We then developed a pooled model including PLWH and HIV-uninfected individuals to
test the adjusted effect of HIV on 6-MWD as well as the potential interaction of HIV and any
significant predictors of 6-MWD. HIV had a significant, independent association with
6-MWD, with PLWH having an average 19.9 meters shorter 6-MWD (95% CI = -34.0- -5.9,
P = 0.005) after adjusting for age, race, weight, height, smoking pack-years, SGRQ, DLCO%
and FEV1%. Additionally, there were two significant interactions, one between pack-year
smoking and HIV (beta = -0.9, P = 0.033, Fig 1a) and one between age and HIV (beta = -1.4,
P = 0.036, Fig 1b) to predict 6-MWD.
Discussion
We evaluated the relationships of HIV status, demographic and clinical variables, standardized
respiratory questionnaires, and pulmonary function with 6-MWD in a cohort of PLWH and
HIV-uninfected individuals. Although the majority of the cohort was virally-suppressed, HIV
infection had an independent association with decreased 6-MWD, with average 6-MWD for
PLWH approximately 20 meters less than for HIV-uninfected individuals when adjusted for
Impaired physical function in HIV
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covariates. We found that severity of airflow limitation and diffusing capacity impairment
were independent predictors of decreased 6-MWD in PLWH, with only diffusing impairment
being associated with 6-MWD in HIV-uninfected individuals. Worse SGRQ predicted shorter
6-MWD in both groups. HIV-associated variables such as CD4 cell count and ART use were
not associated with 6-MWD.
There is conflicting evidence as to the independent relationship of HIV to physical function
as measured by 6-MWD. During the ART era, two studies in primarily male PLWH and
matched HIV-uninfected individuals did not show an independent effect of HIV on 6-MWD
[9, 29]. A cross-sectional analysis of self-reported data from the Veterans Aging Cohort Study
found very modest difference in physical function between PLWH and HIV-uninfected indi-
viduals. Interestingly, this study concluded that the presence of a co-morbid condition
(chronic pulmonary disease) resulted in significant functional decline in PLWH relative to
HIV-uninfected adults [5]. A study in older men found that all measures of physical perfor-
mance including 6-MWD were significantly lower in PLWH when compared to a normal ref-
erence group [29]. PLWH in the Multicenter AIDS Cohort Study had a faster rate of decline in
accelerated longitudinal gait speed over time when compared to HIV-uninfected men, but the
associated clinical and demographic variables were not elucidated [30]. A recent study in mid-
dle-aged asymptomatic participants found subclinical deficits in physical function among
Table 2. Pearson correlation (P value) of clinical and demographic variables with 6-MWD (m) in PLWH and HIV-uninfected participants. P value interaction
shows the interaction between HIV status and each predictor to predict 6-MWD.
HIV-uninfected PLWH P value for interaction
Age, year 0.0 (0.97) -0.21 (0.0002) 0.037
Female 0.03 (0.73)� -0.01 (0.92)� 0.53
Caucasian 0.29 (0.001)� 0.09 (0.10)� 0.13
Pitt Site -0.08 (0.3)� -0.37 (<0.0001)� 0.009
Height, cm -0.07 (0.46) 0.01 (0.85) 0.50
Weight, kg -0.29 (0.0007) -0.18 (0.001) 0.37
Pack-year -0.11 (0.22) -0.29 (<0.0001) 0.032
Illicit drug usage 0.00 (>0.9)� 0.01 (0.88)� 0.72
Hemoglobin, g/dL 0.11 (0.24) -0.01 (0.87) 0.31
VL, copies/ml - - 0.15 (0.012) - -
CD4, cell/μL - - 0.02 (0.69) - -
ART - - -0.09 (0.13) - -
SBP, mmHg -0.08 (0.35) -0.05 (0.41) 0.77
DBP, mmHg -0.06 (0.49) -0.02 (0.76) 0.72
FEV1% post-BD 0.25 (0.004) 0.42 (<0.0001) 0.11
FVC% post-BD 0.20 (0.022) 0.42 (<0.0001) 0.06
FEV1/FVC post-BD 0.14 (0.10) 0.19 (0.001) 0.56
DLCO % 0.21 (0.019) 0.31 (<0.0001) 0.30
MMRC score -0.24 (0.005) -0.27 (0.0002) 0.17
SGRQ score -0.39 (<0.0001)� -0.24 (<0.0001)� 0.95
6-MWD: Six minute walk distance; PLWH: People living with HIV; Pack-year: median number packs of cigarettes smoked per day multiplied by number of years
smoking; VL: HIV viral load; CD4: CD4 T-lymphocyte count; ART: antiretroviral therapy use; SBP: systolic blood pressure; DBP: diastolic blood pressure;FEV1%:
forced expiratory volume in one second; FVC%: forced vital capacity; BD: bronchodilator test; DLCO: diffusing capacity for carbon monoxide adjusted for hemoglobin
and carboxyhemoglobin; % = percent-predicted; MMRC: Modified Medical Research Council dyspnea score; SGRQ: St George’s Respiratory Questionnaire;
� Spearman correlation (P value).
P <0.003 are significant after adjusting for multiple comparison.
https://doi.org/10.1371/journal.pone.0212975.t002
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Table 3. Predictors of 6-MWD (m) in PLWH and HIV-uninfected participants from multivariate regression analysis.
PLWH� HIV-uninfected ��
Beta (95%CI) P value Beta (95%CI) P value
Age, year -1.02 (-1.8- -0.3) 0.009 NS NS
Caucasian 25.6 (9.4–41.9) 0.002 NS NS
Weight, kg -1.1 (-1.6- -0.7) <0.001 -0.7 (-1.4 - -0.005) 0.048
Height, cm 1.6 (0.7–2.5) <0.001 NS NS
Pack-years -0.7 (-1.2- -0.3) 0.003 NS NS
FEV1% post-BD ��� 0.5 (0.01–1.0) 0.033 NS NS
DLCO % 0.6 (0.1–1.1) 0.005 1.3 (0.6–2.0) 0.001
SGRQ -0.9 (-1.4- -0.4) 0.001 -1.7 (-2.4 - -0.9) < 0.001
Constant 265.0 (95.9–434.2) 0.031 425.6 (343.8–507.5) <0.001
�n = 289, three outliers were removed, R-square = 0.41
Model is adjusted for site.
��n = 127, three outliers were removed, R-square = 0.23
��� FVC% post could be replaced for FEV1% post with b = 0.6 (P = 0.035)
NS = Not statistically significant.
6-MWD: Six minute walk distance; PLWH: People living with HIV; Pack-year: median number packs of cigarettes smoked per day multiplied by number of years
smoking; FEV1: forced expiratory volume in one second; % = percent-predicted; DLCO: diffusing capacity for carbon monoxide adjusted for hemoglobin and
carboxyhemoglobin; SGRQ: St George’s Respiratory Questionnaire; FVC: forced vital capacity;
https://doi.org/10.1371/journal.pone.0212975.t003
Fig 1. Relationship between 6-MWD, age and pack-year smoking. (A) relationship between age and 6-MWD in
PLWH and HIV-uninfected individuals, P for interaction = 0.033 (B) relationship between pack-year smoking and
6-MWD in PLWH and HIV-uninfected individuals, P for interaction = 0.036. These figures show that higher pack-
year smoking and older age decrease 6-MWD more in the PLWH compared to the HIV-uninfected group. Gray area
represents 95%CI of regression line.
https://doi.org/10.1371/journal.pone.0212975.g001
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PLWH [31]. Our study involved a more diverse population and revealed an independent effect
of HIV on physical function. PLWH had shorter 6-MWD even after adjusting for potential
clinical differences between PLWH and HIV-uninfected individuals. Differences from previ-
ous work likely result from differences in cohorts and measurements, as well as differences in
ART regimens.
We found overlapping risk factors for decreased 6-MWD in PLWH and HIV-uninfected
individuals, but also several unique predictors. First, DLCO impairment was a common predic-
tor of low 6-MWD in both groups. The relationship between DLCO impairment and decreased
6-MWD is likely multifactorial, involving pulmonary vascular disease, airway obstruction,
emphysema and inflammation [2]. Next, our findings of an independent relationship between
SGRQ and 6-MWD are consistent with other studies, indicating that pulmonary symptom
burden predicts lower walk distance [32, 33]. HIV infection and smoking share common path-
ways affecting pulmonary function, and PLWH may be more susceptible to the damaging
effect of tobacco smoking [34]. Our finding that smoking (when overall burden of smoking in
pack-years was relatively low) and impaired pulmonary function predict the 6-MWD only in
PLWH suggests that at similar levels of spirometric dysfunction, PLWH have heightened sus-
ceptibility to functional impairment.
Other HIV-related factors such as CD4 cell count, HIV viral load, and use of ART were not
related to 6-MWD, consistent with findings in previous studies [29]. In contrast, a prior study
found that markers of HIV treatment success including higher CD4 counts and undetectable
viral load were associated with improved physical function [35]. The high levels of well-con-
trolled HIV within this cohort may have limited ability to assess the impact of these variables.
Duration of HIV, nadir CD4 and zenith viral level may influence 6-MWD, but these data were
not uniformly available in our cohort. Our findings do suggest that while the observed decline
in physical function is related to HIV infection, it is likely independent of the level of
immunosuppression.
It is possible that there are extra-pulmonary causes for reduced 6-MWD in PLWH. The
associations between cardiac function, anemia and fatigue in HIV are well-known [3, 36]. Our
study did not find an association between anemia and 6-MWD, likely due to the normal
hemoglobin values among our study participants. We also did not systematically evaluate car-
diovascular disease. Muscle wasting in the ART era is no longer a primary determinant of fit-
ness [9]; however, aging, HIV infection and ART all have an additive effect on metabolism,
pharmacokinetics, and immune function in PLWH which may contribute to declines in physi-
cal function [37]. A recent study indicated that PLWH have persistent inflammation, immune
activation, and atypical skeletal muscle profiles that lead to asynchronous muscle aging [31].
Such effects of the virus may explain our finding that PLWH experience accelerated functional
decline with age.
Underdiagnoses of co-morbidities is frequent in PLWH [8]. Our findings may have diag-
nostic and therapeutic implications by defining PLWH at higher risk of impaired physical
function. The relationship of physical fitness to HIV-related variables is important, and by
using performance-based measures of function, our study provides an initial assessment of the
clinical and physiological determinants of cardiorespiratory fitness in PLWH when compared
to an HIV-uninfected group.
The magnitude of differences observed between PLWH and uninfected participants is very
similar to the minimum clinical important difference of 30.1 m [38] and has the potential to
predict poorer health status, greater risk of disability, and higher morbidity. This finding
emphasizes the importance of identifying modifiable risk factors for impaired physical perfor-
mance including chronic airway obstruction in PLWH. Subjective assessment of respiratory
symptoms, for example via SGRQ, may be a predictor of declining functional status and
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should prompt clinicians to implement strategies such as smoking cessation to improve func-
tional capacity. Understanding factors that influence ambulatory function could have direct
implications for guiding appropriate diagnostic evaluation of underlying disease processes in
PLWH.
There are several limitations of our study. We used 6-MWD and not VO2, the gold stan-
dard for aerobic exercise capacity [39]. However, we believe that 6-MWD is a viable and
readily-available surrogate as VO2 requires expensive equipment and trained staff, and the
association between 6-MWD and VO2 peak has been found to be consistent [39]. We also did
not assess for clinical pneumonia or colonization with respiratory organisms that have been
shown to contribute to airway obstruction and could potentially affect 6-MWD [40]. We also
had a smaller HIV-uninfected group that may have limited our power to see relationships
between pulmonary function and 6-MWD. A larger, more diverse and longitudinal study of
PLWH is also necessary for validation of impaired physical function as a prognostic indicator
in this population.
Using a performance-based measure of function, we found that HIV infection was an inde-
pendent predictor of decreased physical function and that impaired pulmonary function test
and diffusing capacity abnormalities contribute to decreased 6-MWD. Pulmonary and/or car-
diovascular disease in PLWH can confer an increased risk of morbidity making screening and
early intervention important for this high-risk group. Impaired physical fitness, based on sub-
jective or objective findings, may trigger clinicians to pursue further diagnostic workup,
including assessing for underlying airflow obstruction or diffusion impairment. Research into
clinical and molecular pathways leading to loss of physical function could help in understand-
ing causes of functional impairment in this population.
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